@HealthQuant

REAL Physician Influence. Time to bring your KOL programming into the digital age! Tweets by @chimoose

 Austin, TX
healthquant.com
Joined July 2018
  • Tweets303
  • Following995
  • Followers323
108Media
Looking to find the perfect combination of strengths in KOLs and online influencers? Our latest blog post uncovers the secrets of multi-layered, segmented influencer lists. Stay tuned for expert insights! #KOL #MedAffairs #PharmaMarketing #MedTech buff.ly/3PhDGlB
1
5
389
This could make things interesting - Viking's dosing protocols look like a promising differentiator from Lilly and Novo biopharmadive.com/news/vikin…

Viking shares surge on updated obesity drug data

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

biopharmadive.com
1
525
It'll be interesting to see how Curium does head-to-head vs @Novartis - endpoints.news/fda-approves-… by @Nicole_DeFeudis via @endpts

FDA approves first radioligand generic, setting up rivalry with Novartis

FDA approves Curium's Bexlutry, a radioligand equivalent to Novartis' Lutathera for GEP-NETs, after Curium won a patent lawsuit in Delaware.

endpoints.news
1
64
HealthQuant retweeted
Petros Grivas@PGrivasMDPhDSep 3
Fantastic meeting #IUCS26 @urologysummit led by @gbanna74 @ravikanesvaran international colleagues, great speakers @montypal @neerajaiims @DrYukselUrun @dr__mukherji @ProfSyedHussain @ParamMariappan @JimCatto @nataliagandur @OncoAlert @IBCG_BladderCA @BladderCancerUS @koshkin85
International Urology Cancer Summit
@urologysummitSep 3
🚀 Opening #IUCS26 | From a meeting to a global GU oncology community The opening session highlighted the vision behind IUCS and the creation of IUCS CIC, a non-profit Community Interest Company dedicated to advancing multidisciplinary care, translational research and clinical education across genitourinary cancers. ⚪ Building an international and multidisciplinary GU oncology community ⚪ Accelerating evidence-based innovation ⚪ Connecting translational research with everyday clinical practice ⚪ Strengthening education, collaboration and investigator-led research ⚪ Bringing together expertise across countries and healthcare systems ⚪ Keeping the ultimate goal clear: better outcomes for our patients Great to see the community gathered in Guildford and ready for two days of science, discussion and collaboration. With leadership and contributions from @gbanna74 @ravikanesvaran @PasRescigno @alison_tree @amg120395 @ManiamAkash @neerajaiims @montypal @PGrivasMDPhD @ParamMariappan @DrYukselUrun @dmukherji @nataliagandur @MicheleMaffezz @yekeduz_emre and the wider #IUCS26 faculty. @myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb #GUOncology #UroOnc #ClinicalResearch #MedicalEducation #GlobalOncology
1
12
32
2,217
Love that @EliLillyandCo is creating an ecosystem around their flagship products: Eli Lilly invests in Oura to support patients on GLP-1 drugs endpoints.news/eli-lilly-inv… #pharma #feedly

Eli Lilly invests in Oura to support patients on GLP-1 drugs

Eli Lilly takes an equity stake in smart ring maker Oura to back patients on its GLP-1 drugs; deal size undisclosed.

endpoints.news
47
This opens some potentially interesting doors: @Merck wins first approval of a PCSK9 cholesterol pill biopharmadive.com/news/merck… #pharma #feedly

Merck wins first approval of a PCSK9 cholesterol pill

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.  

biopharmadive.com
47
Do you remember when you joined X? I do! #MyXAnniversary
14
If you’re in Stockholm for #EHA2026, check out Dr. Stephen Schuster’s presentation of our vispa-cel data to hear about long-term durability after a single dose of vispa-cel in patients with relapsed or refractory B cell non-Hodgkin lymphoma. #CellTherapy #CRISPR $CRBU
2
11
597
HealthQuant retweeted
Ankit Gupta
@aguptaJun 12
really great to see @tamarindbio land a unique deal that i think may be a bellwether for more software in pharma
Deniz Kavi
@kavi_denizJun 10
We’re proud to share that @TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models trained on over $1B worth of Lilly proprietary data to the biotech ecosystem. Tamarind will power TuneLab’s scalable drug discovery workflows and model inference.
2
43
6,454
This could come in handy!
Curiosity
@MAstronomers26 May 2025
If you ever get lost in the Milky Way galaxy, this is your map to get back to EARTH.
41
HealthQuant retweeted
LARVOL
@Larvol24 May 2025
Ahead of the @ASCO-2025, @Larvol CLIN spotlights the top companies driving the future of cancer research. Get the latest #ASCO25 updates as they happen: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights | @ADesaiMD | @HHorinouchi | @DrRiyazShah | @FordePatrick | @lungoncdoc | @matteolambe | @ErikaHamilton9 | @PTarantinoMD | @DrChoueiri | @AndreaNecchi | @GillSharlene | @mtmdphd | @SuyogCancer
11
24
10,788
Replying to @tapshah21
@tapshah21 Hi Tapan! Yesterday my app stopped returning user data when calling the X ID user endpoint. Nothing in the documentation implies that was intentionally deprecated; can you please help?
2
47
PS I’ve had a Basic plan for a couple of years and have had no problems thus far …
26
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. biopharmadive.com/news/obesi… #pharma #feedly via @BioPharmaDive

Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.

Amgen’s MariTide readout Tuesday was the first domino to fall in a series of data readouts that could reshape expectations for the weight loss drug market.

biopharmadive.com
1
120
This is one to watch: Startup led by John Maraganore raises $135M to build ‘future of RNAi’ biopharmadive.com/news/city-… #pharma #feedly #biotech

Startup led by John Maraganore raises $135M to build ‘future of RNAi’

“The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

biopharmadive.com
1
221
Interesting #MedTwitter stats: Comparing monthly twitter posts from global doctors, Posts from January-June of 2023 and 2024, physician posts were slightly down (February was actually up 2%). 1/2
1
1
1
285
2/2 But July, August and September of 2024 were each significantly higher than the same months in 2023. I'm encouraged that doctors are coming back. We'll keep watching! #MedTwitter #HCSM #HCSMEU
24
Thanks @BioPharmaDive! Which conferences will YOU be attending? biopharmadive.com/news/top-b… #Pharma #Biotech #PharmaMarketing

The top biopharma conferences remaining in 2025

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch the rest of 2025. 

biopharmadive.com
14
Man, that is a tough analysis - but it's hard to argue. We have to find different ways ...
Andrew Joseph@DrewQJoseph26 Sep 2024
The Bluebird layoffs this week "offered another reminder that groundbreaking genetic medicines capable of transforming the lives of people with inherited disease are not now — and may never become — a sustainable business." via @adamfeuerstein statnews.com/2024/09/26/gene…

Gene therapy for sickle cell disease remains a tough business model — and may never work

Gene therapy for sickle cell disease remains a tough business model — and may never work, @adamfeuerstein writes.

statnews.com
28
Here are some things every guy should know about the most commonly diagnosed cancer in men. spr.ly/6013osbFb

5 Things Every Guy Needs to Know About Prostate Cancer Screening

From when to start to what it's like, here's everything guys need to know about screening for prostate cancer — the most commonly diagnosed cancer in men.

houstonmethodist.org
1
273
Thanks to @JNJInnovMed for their Transparency Report - and to @brianreid's Cost Curve newsletter for pointing us to it!
Greg Matthews
@chimoose26 Sep 2024
Kudos to @JNJInnovMed for their excellent & comprehensive Transparency Report, which Cost Curve (@brianreid) calls the best in the industry. transparencyreport.janssen.c… #Pharma #HealthInnovation #DrugPricing

Transparency Report & Issue Briefs

policyresearch.jnj.com
1
1
41
Nice work by @EliLillyandCo on their #Olympics message: youtu.be/2paOxynX7aQ?si=hLKN…

One Body | Lilly, A Medicine Company

You only get one body. So let’s fight to keep it healthy.This is ...

youtube.com
22
Load more